<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44397">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528318</url>
  </required_header>
  <id_info>
    <org_study_id>03-CL-1401</org_study_id>
    <nct_id>NCT02528318</nct_id>
  </id_info>
  <brief_title>Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Controlled Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Windtree Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Windtree Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of
      lucinactant for inhalation, administered as an aerosolized dose in up to four escalating
      doses to preterm neonates 26 to 28 weeks gestational age who are receiving nasal continuous
      positive airway pressure (nCPAP) for respiratory distress syndrome (RDS) compared to
      neonates receiving nCPAP alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of Lucinactant for Inhalation</measure>
    <time_frame>Day 7</time_frame>
    <description>Assessed during dosing by recording adverse reactions, oxygen saturation levels, and serum electrolytes; and following dosing by recording complications of prematurity and signs of worsening respiratory distress as evidenced by the need for increased respiratory support and supplemental oxygen.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Aerosolized lucinactant (Medium Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium Dose: Lucinactant for inhalation with nCPAP; 1 repeat dose will be allowed if repeat dosing criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosolized lucinactant (High Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose: Lucinactant for inhalation with nCPAP; 1 repeat dose will be allowed if repeat dosing criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosolized lucinactant (High Extension 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Extension 1: Lucinactant for inhalation with nCPAP; 1 repeat dose will be allowed if repeat dosing criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosolized lucinactant (High Extension 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Extension 2: Lucinactant for inhalation with nCPAP; 1 repeat dose will be allowed if repeat dosing criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nCPAP alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nCPAP therapy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucinactant for inhalation</intervention_name>
    <description>Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)</description>
    <arm_group_label>Aerosolized lucinactant (Medium Dose)</arm_group_label>
    <arm_group_label>Aerosolized lucinactant (High Dose)</arm_group_label>
    <arm_group_label>Aerosolized lucinactant (High Extension 1)</arm_group_label>
    <arm_group_label>Aerosolized lucinactant (High Extension 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nCPAP alone</intervention_name>
    <description>nCPAP therapy</description>
    <arm_group_label>nCPAP alone</arm_group_label>
    <other_name>nasal continuous positive airway pressure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent from a legally authorized representative.

          2. Gestational age 26 to 28 completed weeks post menstrual age (PMA).

          3. Successful implementation of controlled nCPAP within 90 minutes after birth.

          4. Spontaneous breathing.

          5. Chest radiograph consistent with RDS.

          6. Within the first 20 hours after birth, requires an nCPAP of 5 to 6 cm H2O of 0.25 to
             0.50 that is clinically indicated for at least 30 minutes. Transient (&lt;10 minutes)
             FiO2 excursions below 0.25 or above 0.50 do not reset the 30 minute requirement.

        Exclusion Criteria:

          1. Heart rate that cannot be stabilized above 100 beats/minute within 5 minutes of
             birth.

          2. Recurrent episodes of apnea occurring after the initial newborn resuscitation period
             (ie, 10 minutes after birth) requiring intermittent positive pressure breaths using
             inflating pressures above the set CPAP pressure administered manually or mechanically
             through any patient interface.

          3. A 5 minute Apgar score &lt; 5.

          4. Major congenital malformation(s) and cranial/facial abnormalities that preclude
             nCPAP, diagnosed antenatally or immediately after birth.

          5. Other diseases or conditions potentially interfering with cardiopulmonary function
             (eg, hydrops fetalis or congenital infection such as TORCH).

          6. Known or suspected chromosomal abnormality or syndrome.

          7. Prolong rupture of membranes (PROM) &gt; 2 weeks.

          8. Evidence of hemodynamic instability requiring vasopressors or steroids for
             hemodynamic support and/or presumed clinical sepsis.

          9. Need for endotracheal intubation and mechanical ventilation.

         10. Has been administered: another investigational agent or investigational medical
             device, any other surfactant agent, steroid treatment after birth.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>26 Weeks</minimum_age>
    <maximum_age>28 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Simonson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Windtree Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Segal, MD, FACP</last_name>
    <phone>215-488-9450</phone>
    <email>rsegal@windtreetx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Gonzalez</last_name>
      <phone>909-558-5830</phone>
      <email>bregonzalez@llu.edu</email>
    </contact>
    <investigator>
      <last_name>Yona Nicolau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sharp Mary Birch Hospital for Women and Newborns</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Gray</last_name>
      <phone>302-733-2247</phone>
      <email>kgray@christianacare.org</email>
    </contact>
    <investigator>
      <last_name>Michael Antunes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen D'Ugard</last_name>
      <phone>305-585-6527</phone>
      <email>Cdugard@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Cristina Navarrete, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Nason</last_name>
      <phone>502-629-5038</phone>
      <email>jennifer.nason@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Dan Stewart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Schmid</last_name>
      <phone>402-559-1139</phone>
      <email>cindy.schmid@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Ann Anderson Berry, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Neonatology Associates</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital - Morgan Stanley Children's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilyn Weindler</last_name>
      <phone>212-305-3577</phone>
      <email>mw289@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Tina Leone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Hanover Regional Medical Center</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Kurtz</last_name>
      <phone>910-667-2677</phone>
      <email>danielle.kurtz@ccneo.net</email>
    </contact>
    <investigator>
      <last_name>Sheri Carroll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Guenther</last_name>
      <phone>509-868-9933</phone>
      <email>karen.guenther@providence.org</email>
    </contact>
    <investigator>
      <last_name>Joseph W Kaempf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyse LaLiberte</last_name>
      <phone>401-274-1122</phone>
      <email>alaliberte@wihri.org</email>
    </contact>
    <investigator>
      <last_name>Martin Keszler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Brown</last_name>
      <phone>403-944-3903</phone>
      <email>nicole.brown2@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Ayman Abou Mehrem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Alexandria Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Van Os</last_name>
      <phone>780-735-4111</phone>
      <email>sylvia.vanos@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Georg Schmolzer, MBBS MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afsheen Ayaz</last_name>
      <phone>416-480-6800</phone>
      <email>afsheen.ayaz@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Michael Dunn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Bedikian</last_name>
      <phone>514-934-1934</phone>
      <email>caroline.bedikian@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Guilherme Sant'Anna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Dr Sotero Del Rio</name>
      <address>
        <city>Santiago</city>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Garcia</last_name>
      <phone>+56223536239</phone>
      <email>andregarcia.v@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Patricia Mena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Dios</name>
      <address>
        <city>Santiago</city>
        <zip>8350488</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcela Urzua</last_name>
      <phone>﻿﻿+56993228312</phone>
      <email>maurzua@med.puc.cl</email>
    </contact>
    <investigator>
      <last_name>Jose Antonio Salinas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.U. nr2im. Dr. Jana Biziela Oddzial Kliniczny N. W. Z. Intensywna Terapia Noworodka wraz z Wgjazdowy m Zespolem N</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorksie</state>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Korbal, MD PhD</last_name>
      <phone>+48523655568</phone>
      <email>pkorbal@amb.bydgoszcz.pl</email>
    </contact>
    <investigator>
      <last_name>Piotr Korbal, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowja Matki Polki Klinika Neonatologii</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Gulczynska, MD PhD</last_name>
      <phone>+48422711042</phone>
      <email>ewagulcz@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Ewa Gulczynska, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SP ZOZ Szpital Uniwersytecki w Krakowie, Oddzial Neonatologii</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im. Ks, Anny Mazowieckiej Klinika Neonatologii</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>00-315</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Borszewska-Kornacka, MD PhD</last_name>
      <phone>+48225966155</phone>
      <email>mariak@szpitalkarowa.pl</email>
    </contact>
    <investigator>
      <last_name>Maria Borszewska-Kornacka, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ginekologiczno-Polozniczy Szpital Klinicznym UM im. Karola Marcinkowskiego w Poznan i u Katedra Neonatologii</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-535</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janusz Gadzinowski, MD PhD</last_name>
      <phone>+48618419270</phone>
      <email>jgadzin@gpsk.am.poznan.pl</email>
    </contact>
    <investigator>
      <last_name>Janusz Gadzinowski, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Chile</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 17, 2017</lastchanged_date>
  <firstreceived_date>August 17, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
